Preliminary results from the FULCRUM-VT trial point to a safer, more effective way to treat ventricular tachycardia—a dangerous heart rhythm disorder that can lead to sudden cardiac arrest.

Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title, registration ...

The UAB Internal Medicine Residency program was still able to hold its 9th annual Code Week from Monday, July 6 through Thursday, July 9 despite the COVID-19 pandemic. Code Week is designed to give ...